No Data
No Data
No Data
No Data
No Data
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing
GlobeNewswire19:59
Pasithea Therapeutics Begins U.S. Trial for Cancer Treatment
InvestingFeb 13 21:04
Top Premarket Decliners
VCI Global (VCIG) shares slumped more than 36% Friday premarket after the company priced a $2.8 million offering of stock and warrants. SEALSQ (LAES) shares tumbled 23%, a day after the company closed
MT NewswiresJan 12 20:43
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients
Pasithea Therapeutics (KTTA) shares rose 12% in recent Tuesday trading after the company got US Federal Drug Administration clearance to assess PAS-004 in cancer patients with advanced solid tumors. P
MT NewswiresJan 3 04:16
Pasithea Conducts 1-for-20 Reverse Stock Split, Gets FDA Okay for Study
Seeking AlphaJan 2 22:11
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout
GlobeNewswireJan 2 21:35
No Data
No Data